Results 31 to 40 of about 2,461,363 (302)
Antiplatelet therapies in diabetes
Diabetic Medicine, 2020 AbstractCardiovascular complications remain the main cause of mortality and morbidity in diabetes. This is related to advanced vascular pathology in this population, together with an enhanced thrombotic environment. The increased risk in thrombosis is secondary to platelet hyper‐reactivity and increased levels and/or altered activity of coagulation ...
R. C. Sagar, K. M. Naseem, R. A. Ajjan
openaire +3 more sources
Antiplatelet activity should be measured routinely: no [PDF]
, 2009 Antiplatelet agents such as aspirin, clopidogrel, anddipyridamole are effective in secondary stroke pre-vention with single agents reducing risk by 15 % to 20%1–3; the addition of a second agent (eg, combining aspirin and dipyridamole) doubles this ...
Philip M. W. Bath, Bath, Philip M.W.
core +1 more source
Cerebrovascular Diseases Extra, 2016 Background and Purpose: The optimal use of antiplatelet therapy for intracranial branch atheromatous disease (BAD) is not known. Methods: We conducted a prospective multicenter, single-group trial of 144 consecutive patients diagnosed with probable BAD ...
Teruo Kimura +13 more
doaj +1 more source
Study design of endoscopic polypectomy on clopidogrel (EPOC): A randomised controlled trial
Contemporary Clinical Trials Communications, 2019 Concurrent cardiovascular disease and antiplatelet use (clopidogrel, prasugrel and ticagrelor) use poses a significant peri-endoscopic management challenge with a paucity of high-quality evidence available.
Shara Ket +8 more
doaj +1 more source
Российский кардиологический журнал, 2014 The review provides the current information about the role of antiplatelet therapy in the cardiovascular prevention in patients with coronary artery disease and coronary revascularization.
Yu. I. Grinschtein +2 more
doaj +1 more source
Clinical and Applied Thrombosis/Hemostasis, 2021 This study aimed to investigate the long-term safety and benefits of antiplatelet therapy in patients with cerebral infarction with thrombocytopenia, as evidence regarding this was limited.
Shijie Guo MD +7 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Introduction: Transjugular intrahepatic portosystemic shunt (TIPS) is an effective way to improve portal hypertension, however, the role of anticoagulation or antiplatelet therapy following TIPS remains controversial.
Xiaotong Xu +5 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Introduction/Objective Acute intracranial stenting during endovascular thrombectomy (EVT) for ischemic stroke requires intraprocedural antiplatelet therapy (APT) to maintain patency. However, the hemorrhagic risk of combining APT with intravenous thrombolysis (IVT) remains uncertain.
Aaron Rodriguez‐Calienes +75 more
wiley +1 more source
Trails of antiplatelet therapy [PDF]
BMJ, 1994 Editor, - The impressive collaborative overview of antiplatelet therapy for prevention of venous thromboembolism1 raises several question which are of great practical relevance in daily practice. Firstly, this meta -analysis contradicts the recommendations given by consensus panels2 and also the general opinion of experts that aspirin has little or no ...
openaire +2 more sources
Drug interactions and hepatotoxicity of clopidogrel [PDF]
, 2010 Clopidogrel (Plavix¨) is an antiplatelet drug, which is clinically used in combination with aspirin to reduce cardiovascular events in patients undergoing percutaneous coronary intervention or in patients suffering from acute coronary syndromes ...
Zahno, Anja-Christina
core +1 more source